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                                                   ABSTRACT  
Efficacy and Safety of Intravitreal Triamcinolone Acetonide in the 
Management of Recalcitrant Diabetic Macular Edema 
Purpose: To evaluate the safety and efficacy of intravitreal triamcinolone 
acetonide in the management of recalcitrant diabetic macular edema unresponsive 
to laser photocoagulation and the intravitreal anti-VEGF agent, bevacizumab. 
Design: Prospective, non-comparative, interventional study. 
Participants: Twenty-one eyes of seventeen patients with clinically significant 
macular edema(CSME) that failed to respond to laser photocoagulation and 2 doses 
of intravitreal anti-VEGF agent, bevacizumab in which resolution of macular 
edema had not occurred within one month of treatment, as assessed by clinical 
examination and measured by optical coherence tomography (OCT) and are 
recalcitrant. 
Methods: Eyes were diagnosed with recalcitrant diabetic macular edema which 
exhibited best corrected visual acuity (BCVA) of 6/18 or worse, with central 
macular thickness of more than 300 µm (normal 200 µm) were treated with 2 mg of 
intravitreal triamcinolone acetonide; and followed up for a period of 6months at 
intervals of 1 week, 1 month, 3 months and 6 months following the intravitreal 
injection. The visual and anatomic responses were observed as well as 
complications related to the injection procedure and corticosteroid medication. 
Main Outcome Measures: The response to treatment was monitored functionally 
by best corrected visual acuity and anatomically by OCT by measuring central 
macular thickness quantitatively. Potential complications were monitored  
functionally by looking for decrease in visual acuity of one line by Snellen’s chart, 
rise in intraocular pressure greater than 3omm of Hg not responding to anti-
glaucoma medications, progression of cataract, retinal detachment, vitreous 
hemorrhage, and endophthalmitis. 
Results: All patients completed 6 months follow-up period. The mean best 
corrected visual acuity (BCVA) in the eyes that received triamcinolone acetonide 
(TA) was (in decimals) 0.14 ± 0.07 (pre injection), 0.26 ± 0.12 (one week after 
injection of TA), 0.39 ± 0.20 (one month after injection of TA), 0.32 ± 0.15 (3 
months after injection of TA) and 0.18 ± 0.10 (6months after injection of TA; these 
differences  were statistically significant (one-way analysis of variance [ANOVA]; 
Fisher ‘f’ value = 11.804; P < 0.001). The mean central foveal thickness (CFT) in 
eyes with recalcitrant diabetic macular edema that received  triamcinolone  
acetonide  was (in μm) 536.5 ± 115.3 (pre injection), 380.7 ± 95.6 (1 week post 
injection), 280.9 ± 71.6 ( one month post-injection), 283.6 ± 76.8 (three months 
post-injection) and 370.2  ±  114.3 (six months post-injection); these differences  
were statistically significant [one-way ANOVA; Fisher ‘f’ value = 24.4; P < 0.001]. 
The mean HbA1C value was 8.2% at baseline,7.7% at 3 months and 7.7% at 6 
months follow-up; this reduction in mean HbA1C values was not statistically 
significant.( P=0.06 ). The mean intraocular pressure (IOP) in the eyes with 
recalcitrant diabetic macular edema  that received triamcinolone acetonide was (in 
mm Hg) 17.4 ± 2.2  (pre injection), 18.0 ± 2.1 (1 week post injection), 18.4 ±  2.2 ( 
one month post-injection),  18.6 ±  5.12 (three months post-injection) and 20.3  ±  
11.8  (six months post-injection); these differences  were not statistically significant 
(ANOVA; Fisher ‘f’ value = 0.689;  P = 0.6). Of the 18 phakic eyes, four eyes ( 
22.2%) developed cataract following intravitreal injection of triamcinolone 
acetonide for which cataract surgery and intraocular lens implantation were done. 
Severe complications, such as infectious endophthalmitis or retinal detachment, 
were not observed within the follow-up period in the present study. 
Conclusion: Intravitreal  triamcinolone acetonide appears to be effective in the 
management of recalcitrant diabetic macular edema and improvement in best 
corrected visual acuity was statistically significant in the short term (1 month and 3 
months). The effect of intravitreal triamcinolone acetonide appears to be transient, 
necessitating repeat injections 6 months after the first dose. Intravitreal 
triamcinolone acetonide can still be a safe therapeutic option in patients who are 
resistant to conventional laser photo coagulation and intravitreal anti-VEGF agents. 
Further study is warranted to assess the long-term efficacy and safety of 
triamcinolone acetonide and the need for retreatment. 
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